Confirming TDP2 mutation in spinocerebellar ataxia autosomal recessive 23 (SCAR23) by Zagnoli-Vieira G et al.
ARTICLE OPEN ACCESS
Confirming TDP2 mutation in spinocerebellar
ataxia autosomal recessive 23 (SCAR23)
Guido Zagnoli-Vieira, BSc, Francesco Bruni, PhD,* Kyle Thompson, PhD, Langping He, MD, PhD,
Sarah Walker, PhD, Arjan P.M. de Brouwer, PhD, Robert Taylor, PhD, FRCPath, Dmitriy Niyazov, MD,
and Keith W. Caldecott, PhD
Neurol Genet 2018;4:e262. doi:10.1212/NXG.0000000000000262
Correspondence
Dr. Caldecott
k.w.caldecott@sussex.ac.uk
Abstract
Objective
To address the relationship between mutations in the DNA strand break repair protein tyrosyl
DNA phosphodiesterase 2 (TDP2) and spinocerebellar ataxia autosomal recessive 23
(SCAR23) and to characterize the cellular phenotype of primary fibroblasts from this disease.
Methods
We have used exome sequencing, Sanger sequencing, gene editing and cell biology, bio-
chemistry, and subcellular mitochondrial analyses for this study.
Results
We have identified a patient in the United States with SCAR23 harboring the same homozy-
gous TDP2mutation as previously reported in 3 Irish siblings (c.425+1G>A). The current and
Irish patients share the same disease haplotype, but the current patient lacks a homozygous
variant present in the Irish siblings in the closely linked gene ZNF193, eliminating this as
a contributor to the disease. The current patient also displays symptoms consistent with
mitochondrial dysfunction, although levels of mitochondrial function in patient primary skin
fibroblasts are normal. However, we demonstrate an inability in patient primary fibroblasts to
rapidly repair topoisomerase-induced DNA double-strand breaks (DSBs) in the nucleus and
profound hypersensitivity to this type of DNA damage.
Conclusions
These data confirm theTDP2mutation as causative for SCAR23 and highlight the link between
defects in nuclear DNA DSB repair, developmental delay, epilepsy, and ataxia.
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DNA is under constant threat from attack by endogenous and
exogenous electrophilic molecules,1 and DNA topoisomerase
enzymes can introduce DNA breaks as abortive intermediates
of their activity.2–4 Topoisomerase “poisons” such as etopo-
side inhibit the ligation activity of topoisomerase 2 (TOP2),
thereby promoting the formation of abortive DNA double-
strand break (DSB) intermediates that require DSB repair.
DSBs are repaired in cells by either homologous
recombination–mediated repair or by nonhomologous end
joining (NHEJ).2 The repair of TOP2-induced DSBs by
NHEJ involves the enzyme tyrosyl DNA phosphodiesterase 2
(TDP2), which removes trapped topoisomerase peptide from
the 59-termini at the DSB and thereby allows the DNA ends to
be ligated.3–5 The loss of TDP2 in mouse results in reduced
expression of >100 genes in the brain,6 and TDP2mutation in
humans has been associated with intellectual disability, seiz-
ures, and ataxia,6 a disease now denoted as spinocerebellar
ataxia, autosomal recessive 23 (SCAR23). To date, our un-
derstanding of SCAR23 has been limited by the availability of
only 3 Irish siblings with a mutation in TDP2 and by the lack
of availability of fibroblast cell lines from these patients for
molecular and cellular characterization. Here, we have
addressed these limitations and identified an SCAR23 patient
in the United States with the same homozygous TDP2 mu-
tation as present in the Irish siblings, confirming the associ-
ation of this disease with mutated TDP2. In addition, we have
characterized at the molecular and cellular level primary pa-
tient fibroblasts from the current SCAR23 patient.
Methods
Patient case report
The patient is currently a 6-year-old caucasian boy from
the United States presenting with developmental delay,
microcephaly, and failure to thrive. His mother and father
are aged 29 years and 32 years, respectively, and there is no
previous family history of related disease, but there is
possible consanguinity (3rd cousins). The patient started
walking at the age of 14 months and talking at 3 years, his
hearing was reportedly normal, but he did not have audi-
tory brainstem response. The patient is easily fatigued, and
his parents reported that he eats excessively, becomes ir-
ritable, and falls asleep sometimes for days or up to 2
weeks. He is now below the fifth percentile for weight and
5% for height, with a body mass index at <5%. He has
a G-tube and is followed by a dietitian and receives nutri-
tional liquid supplements (PediaSure; Abbott, Lake Forest,
IL). He has a history of constipation and is followed up by
a gastroenterologist. He has a 12-year-old brother who is
also easily fatigued and a 14-year-old maternal half-sister
with attention deficit hyperactivity disorder (ADHD).
The patient has difficulty keeping balance and has an ataxic
gait. He has been tested several times for abnormalities in
blood, urine, and CSF, and by MRI and EEG, and only the
latter is abnormal. Seizures began at the age of 5 months, and
his EEGs show increased slowing and occasional spikes in the
right posterior quadrant, and during drowsiness, he had 2
generalized bursts of polyspike and slow-wave activity at
a frequency of 4–5 Hz. The patient’s 180K oligoarray, very
long chain fatty acids, carbohydrate-deficient transferrin, CSF
lactate, and neurotransmitters and plasma amino acids were
normal.
The patient exhibited several phenotypes consistent with mi-
tochondrial dysfunction such as hypotonia, low energy, fati-
gability, hypersomnia, failure to thrive, short stature,
constipation, neutropenia, hyponatremia, cardiac arrhythmia,
and gastrointestinal dysmotility. Consistent with this, electron
transport chain (ETC) studies on muscle biopsy at age 1 year
showed a severe reduction of complex I + III and II + III
activity, which satisfied the major Walker criteria after cor-
rection for increased citrate synthase activity. CoQ10 de-
ficiency was suggested based on the complex I + III and II + III
deficiency, and his metabolic tests were abnormal with the
high lactate and high lactate/pyruvate ratio. The patient was
placed on ubiquinol, carnitine, and leucovorin, and anecdot-
ally, he responded well (particularly to liposomal ubiquinol,
the active or reduced form of CoQ10) in terms of energy and
developmental progress. He is reportedly no longer sleepy and
lethargic and has a stable gait, but is “still behind” in language
and cognitive skills and is in special education. He still has
idiopathic fevers but has not been admitted to the hospital for
15 months. He does not have as many infections but still has
gastric dysmotility. His seizures have reduced in frequency.
Standard protocol approvals, registrations, and
patient consents
We confirm that we have received approval from an in-
stitutional ethics standards committee for this work, and we
have written informed consent for research from the guardian
of the patient for participation in this study.
Exome sequencing and haplotype analysis
Whole-exome sequencing (WES) (trio study) of the patient was
performed by GeneDx using the Agilent Clinical Research
Exome kit to target the exonic regions and flanking splice
junctions of the genome. These targeted regions were sequenced
simultaneously by massively parallel (NextGen, Irvine, CA)
Glossary
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sequencing on an Illumina HiSeq sequencing system with
100bp paired-end reads. Bidirectional sequence was assembled,
aligned to reference gene sequences based on human genome
build GRCh37/UCSC hg19, and analyzed for sequence var-
iants in the selected genes or regions of interest using a custom-
developed analysis tool (XomeAnalyzer). Capillary sequencing
was used to confirm all potentially pathogenic variants identi-
fied in this individual. Sequence alterations were reported
according to the nomenclature guidelines of the Human
Genome Variation Society. The WES identified a homozygous
splice site mutation (c.425+1G>A) in the TDP2 gene. For
comparison of the current patient with the Irish pedigree
previously reported,6 we conducted haplotype analysis. Var-
iants were considered for homozygosity if they were (1) cov-
ered by at least 4 reads or more, (2) present in 80% of all reads
or more, (3) designated as a substitution, (4) uniquely posi-
tioned in the human genome, and (5) present in the exome
data of both individuals. Homozygous regions were de-
termined using a sliding window, accepting 2 or less homozy-
gous variants per 10 variants assessed.
Mitochondrial preparation and subcellular
fractionation
Mitochondria were prepared as described previously,7 with few
modifications. HeLa cells and fibroblasts (control and patient)
were harvested, resuspended in homogenization buffer (HB
[0.6 M mannitol, 10 mM Tris-HCl pH 7.4, 1 mM (ethylene
glycol-bis(β-aminoethyl ether)-N,N,N9,N9-tetraacetic acid)
(EGTA), 0.1% bovine serum albumin (BSA) (wt/vol]), and
subjected to differential centrifugation. Mitochondria were pel-
leted at 11.000g for 10 minutes at 4°C and resuspended in HB;
the postmitochondrial supernatant was retained after centrifu-
gation (“post-mito spin”). For submitochondrial fraction prepa-
ration, HeLa cell mitochondria (300 μg) were treated with 1.6 μg
of proteinase K on ice for 30minutes, followed by the addition of
5 mM phenylmethanesulfonyl fluoride (PMSF). This fraction
was pelleted at 11.000g for 10minutes at 4°C and resuspended in
HB. Mitoplasts were obtained by resuspending PK-treated mi-
tochondria in 9 volumes of 10 mM Tris-HCl (pH 7.4) and
treated with PK, as described earlier. Inner mitochondrial
membrane proteins were extracted in the presence of 100 mM
Na2CO3, followed by centrifugation at 100.000g for 15 minutes
at 4°C. Proteins (30 μg) from each fraction were loaded onto
12% SDS-PAGE gel, transferred to the polyvinylidene difluoride
(PVDF) membrane, and analyzed by immunoblotting using
primary antibodies to apoptosis inducing factor (AIF) (NEB),
eIF4E (Cell Signalling), EF-Tu (custom made), NDUFB8
(Mitosciences), and TDP2 (see Western Blotting, below).
Cell culture and vectors
Human A549 cells were grown in Dulbecco Modified Eagle
Medium (Gibco, ThermoFisher, Waltham, MA) containing
10% fetal calf serum (FCS), 2 mM glutamine, penicillin (100
units/mL), and streptomycin (100 μg/mL). Human fibroblasts
were grown in Minimum Essential Media (Gibco) containing
15% FCS, 2 mM glutamine, penicillin (100 units/mL), and
streptomycin (100 μg/mL). All cells were grown at 5% CO2 at
37°C. TDP2-mutated patient primary human fibroblasts were
established from a patient’s skin biopsy and were denoted 850-
BR. The control human fibroblast cell line 1-BR.3 (denoted
here for simplicity as 1-BR) was previously derived from an
unrelated normal individual and has been described pre-
viously.8 For complementation experiments, we used 1-BR
cells that were immortalized previously with hTERT (denoted
as 1-BR hTERT) and a derivative of 850-BR immortalized in
the current study by retroviral-mediated hTERT expression
and selected in a medium containing 1 μg/ml puromycin
(denoted as 850-BR hTERT). For complementation with
human TDP2, 850-BR hTERT cells were transfected with ei-
ther empty eGFP-N1 vector or eGFP-N1 construct encoding
GFP-tagged human TDP2 (denoted as TDP2-GFP-N1) and
stable transfectants selected for 21 days by growth in a medium
containing 0.5mg/mLG418 (Gibco, ThermoFisher,Waltham,
MA). TDP2-GFP-N1 was generated by PCR amplification
of the human TDP2 ORF using the primers TDP2_FW
(59-AAAGAATTCATGGAGTTGGGGAGTTGCCTG-39)
and TDP2_RV (59-AAAGGATCCAATATTATATCT
AAGTTGCACAGAAGACC-39) and subcloning the PCR
product into the EcoRI/BamHI sites of eGFP-N1.
CRISPR/Cas9 gene editing
A549 TDP2−/− cells were created as previously reported.9 In
brief, we used a 17-bp (minus the PAM) RNA sequence
targeting TDP2 exon 4 (59-GTAGAAATATCACATCT-39),
which was selected using the tool E-CRISP (e-crisp.org/
E-CRISP/) and cloned into the guide RNA vector #41824
(AddGene). The TDP2 guide construct was cotransfected
with hCas9 expressed from plasmid #41815 (AddGene) using
Amaxa Nucleofector plataform (Lonza, Basel, Switzerland)
Kit T program X-001. Transfected cells were enriched by
selection in 1 mg/mL G418 (Thermofisher) for 5 days before
isolation of single clones and screening for loss of TDP2
expression by Western blotting.
Sanger sequencing
DNA was extracted from 850-BR cells using the DNeasy
Blood & Tissue kit (Qiagen, Manchester, UK). PCR
reactions used Phusion HF-DNA Polymerase (NEB) and
the following primers: TDP2_FW GCCAGTGTT-
GACCTAACCAATGAAGA; TDP2_RV CTGTAGAAA-
TATCACATCTGGGCTGTACC; ZSCAN9_FWATGAAGT
AACCAAGACTGAGGACAGAGAG; and ZSCAN9_RV
AGACCAGCTCAGCCACTGTGTGGATCT. PCR products
were purified before sequencing using a QIAquick PCR purifi-
cation kit (Qiagen).
Western blotting
Anti-TDP2 antibody was used at 1:5000 in Western blotting
and has been described previously.10 Anti-Actin (Sigma
A4700) was used at 1:2000. Western blot assessment of
OXPHOS components in patient primary fibroblasts was
conducted as described previously,11 using antibodies against
NDUFB8 (Abcam cat# ab110242), SDHA (Abcam cat#
ab14715), UQCRC2 (Abcam cat# ab14745), COXI (Abcam
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cat# ab14705), ATP5A (Abcam cat# ab14748), SDHB
(Abcam cat# ab14714), COX II (Abcam cat# 110258), and
VDAC1 (Abcam cat# ab14734).
Clonogenic survival assays
1-BR and 850-BR primary fibroblasts cells were plated onto
feeder layers (see below) and 3 hours later treated with indicated
concentrations of etoposide for 21 days to allow the formation of
macroscopic colonies, which were rinsed in phosphate buffered
saline (PBS) and fixed/stained in 70% ethanol/1% methylene
blue. A549 and TDP2−/− A549 were plated 4 hours before
treatment with the indicated concentrations of etoposide for 12
days and stained as described earlier. The surviving fraction at
each dose was calculated by dividing the average number of
colonies (>50 cells) in treated dishes by the average number in
untreated dishes. For feeder layers, 1-BR cells were irradiated (35
Gy) and plated 24 hours before use at 5 × 104 cells/10 cm dish.
Tyrosyl DNA phosphodiesterase assays
Whole-cell extract (WCE) was prepared by resuspension of
1-BR or 850-BR primary fibroblast cell pellets (1×106cells) in
100μL lysis buffer (40 mM Tris/HCl pH 7.5, 100 mM NaCl,
0.1% Tween-20, 1 mM DTT, 1 mM PMSF, 1x EDTA free
protease cocktail inhibitor), followed by 30 minutes of in-
cubation on ice and mild sonication. The WCE was clarified
by centrifugation for 10 minutes at 4°C at 16000g in
a microfuge and the protein concentration quantified using
the bicinchoninic acid (BCA) assay reagent (ThermoFisher).
Figure 1 TDP2 splice site mutation in an individual from the United States with SCAR23
(A) Pedigree analysis. White symbols:
wild-type TDP2. Black symbols: ho-
mozygosity for the TDP2 splice site
mutation c.425+1G>A (IVS3+1G>A) in
the proband (“1”). Dotted symbols,
heterozygosity for c.425+1G>A (IVS3+
1G>A). (B) Sanger sequencing of the
proband, demonstrating (left) the
homozygous TDP2 mutation c.425+
1G>A (IVS3+1G>A) and (right) the ab-
sence of the ZSCAN9 variant
c914A>G. Patient sequences are
shown at the bottom, and reference
sequences are shown at the top. The
2 nucleotides relevant to the muta-
tions are underlined. (C) Pathologic
features of the Irish and US patients.
(D) Haplotypes of Irish patients
(51670; Irish pedigree) and the cur-
rent patient from the United States
(1583786) carrying the homozygous
c.425+1G>A variant in TDP2. Only the
variants bordering and directly within
the homozygous regions and with
a minor allele frequency of 5% are
shown. Variants are indicated by their
accession number in the dbSNP da-
tabase, and the position of c.425+
1G>A is in bold. The minimal over-
lapping region is delimited by
rs9396886 and rs749338 and is 15.1
Mb in size. Black bars represent the
homozygous haplotype as inferred
from exome sequencing data. TDP2 =
tyrosyl DNA phosphodiesterase 2.
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Clarified WCE (15μg total protein) was incubated with 40
nM TDP2 substrate (Cy5-59Tyrosine-ssDNA19-BHQ) or
TDP1 substrate (BHQ-ssDNA13-39Tyrosine-Cy5) in re-
action buffer (50 mM Tris/HCl pH8.0, 10 mM MgCl2,
80 mM KCl, and 1 mM DTT, 0.05% Tween-20) in a total
volume of 6μL at room temperature, and Cy5 fluorescence
was measured at 640 nm at the indicated time intervals on
a BMG PHERAstar plate reader.
DSB repair assays
Cells were grown on coverslips until confluent and then
treated for 30 minutes with 25μM etoposide or irradiated
with x-rays (2 Gy). After treatment, cells were rinsed and
fixed for 10 minutes in PBS containing 4% para-
formaldehyde at the indicated time points. Cells were
permeabilized (20 minutes in PBS-0.2% Triton X-100),
blocked (1 hour in PBS-5% BSA), and incubated with anti-
γH2AX (Millipore, 05-636, 1:2500) and anti-CENP-F
(Abcam, ab5, 1:2500) antibodies for 3 hours in PBS con-
taining 5% BSA. Cells were then washed (3 × 5 minutes in
PBS containing 0.1%Tween-20), incubated for 1h with the
corresponding Alexa Fluor conjugated secondary antibody
(1:1000, 5% BSA), and washed again as described earlier.
Finally, cells were counterstained with DAPI (Sigma,
Gillingham, UK) and mounted in VECTASHIELD (Vector
Labs, Peterborough, UK). Images were acquired on an
automated wide-field microscopy Olympus ScanR system
(motorized IX83 microscope) with ScanR Image Acquisi-
tion and Analysis Software, 20×/0.45 (LUCPLFLN
20×PH) dry objectives, and Hamamatsu ORCA-R2 digital
CCD camera C10600. For the analysis of G0/G1 cells in
patient primary fibroblasts, only CENP-F-negative cells
Figure 2 Greatly reduced TDP2 protein and activity in 850-BR patient fibroblasts
(A) TDP2 and actin protein levels in WCE (20 μg total protein) from 1-BR normal and 850-BR patient primary fibroblasts, as measured by immunoblotting. (B)
TDP1 and TDP2 biochemical assay. Hydrolysis of a 39-phosphotyrosyl (TDP1 assay) or 59-phosphotyrosyl (TDP2 assay) bond releases the associated Cy5
fluorophore and alleviates quenching by the BHQ located on the opposite oligonucleotide terminus, resulting in elevated fluorescence at 640 nm. (C) Real-
time (0–30minutes)measurements of 59-tyrosyl DNA phosphodiesterase activity (TDP2 assay) in reaction buffer (as a negative control) orWCE (15μg protein)
from 1-BR normal or 850-BR patient primary fibroblasts, using the single-stranded oligonucleotide (40 nM) with a 59-phosphotyrosyl-linked Cy5 fluorophore
and 39-BHQ. (D) Real-time measurements (0–30 minutes) of 39-tyrosyl DNA phosphodiesterase (TDP1 assay) conducted as above but using a 39-phospho-
tyrosyl-linked Cy5 fluorophore and 59-BHQ. Data are mean of 3 independent experiments ±SEM. Statistical significance was determined by two way analysis
of variance (ANOVA). ***p < 0.001. BHQ = black hole quencher; TDP2 = tyrosyl DNA phosphodiesterase 2; WCE = whole-cell extract.
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were scored. For A549 and A549 TDP2−/−, cells were gated
to the G1 population according to the DAPI profile of
ScanR Image Analysis Software. For patient fibroblast
complementation experiments, cells were gated accord-
ingly to eGFP expression on ScanR Analysis Software, in
addition to the G1 population according to the DAPI
content.
Results
We recently described mutations in TDP2 in three Irish
patients from the same family with intellectual disability,
seizures, and ataxia, a disease now denoted as spinocerebellar
ataxia 23 (SCAR23)6. Here, we describe a 6-year-old patient
in the United States with very similar pathology including
developmental delay, epilepsy, and ataxia and in whom we
identified by whole-exome and Sanger sequencing possesses
the same homozygous splice site mutation in TDP2 (c.425+
1G>A) (figure 1, A–C). Whether there is a connection be-
tween the current patient and the Irish family is not clear, but
a comparison of the WES data from the two families revealed
that the two apparently unrelated affected individuals of
whom their exome was sequenced share the same homozy-
gous haplotype of ;15.1 Mb (figure 1D). It is important to
note that in contrast to the Irish patients, however, the current
patient lacks the mutation c.914A>G (p.His305Arg) in
ZNF193, a zinc finger protein of unknown function (figure
1B, right). We previously concluded that this variant was not
disease causing in the Irish patients,6 and the absence of this
variant in the current patient confirms that this and also that
TDP2 mutation is the cause of SCAR23.
To enable additional molecular and cellular analyses of
SCAR23, we generated primary fibroblasts (denoted 850-BR)
from a skin biopsy kindly provided by the current patient.
Western blotting failed to detect TDP2 protein in the 850-BR
patient fibroblasts (figure 2A), consistent with the lack of
detectable TDP2 protein previously reported in lympho-
blastoid cells from the Irish patients.6 The absence of de-
tectable TDP2 protein in the lymphoblastoid cell lines was
explained by the impact of the TDP2 mutation on splicing,
which resulted in nonsense-mediated decay and greatly re-
duced (<20%) levels of TDP2 mRNA.6 To confirm the im-
pact of the splice site mutation on TDP2 activity, we used
a highly sensitive tyrosyl DNA phosphodiesterase bio-
chemical assay. This assay uses a single-stranded oligonucle-
otide substrate in which hydrolytic release of a Cy5-labeled
tyrosine moiety present on one terminus of the oligonucle-
otide results in increased fluorescence due to evasion of
a black hole quencher present on the opposite terminus
(figure 2B). By situating the fluorescent-labeled tyrosine on
either the 39 or 59 terminus, this assay can detect TDP1 or
TDP2 activity, respectively. Although whole-cell extract from
normal 1-BR human fibroblasts exhibited robust 59-tyrosyl
DNA phosphodiesterase activity, 850-BR patient fibroblasts
did not (figure 2C). The small amount of activity observed in
Figure 3 Reduced DSB repair in TDP2-mutated patient fibroblasts and A549 cells after topoisomerase 2-induced DNA
damage
(A) DSBs were measured by γH2AX
immunostaining in normal 1-BR and
patient 850-BR primary fibroblasts be-
fore and after treatment for 30 minutes
with DMSO vehicle or 25 μM etoposide
(“0”), followed by subsequent in-
cubation in a drug-free medium for the
indicated repair periods. (B) DSBs were
measured as above, in wild-type A549
cells and in A549 cells in which TDP2was
deleted by CRISPR/Cas9 gene editing
(TDP2−/− A549). The level of TDP2 and
actin (loading control) in the cell lines
used for these experiments is shown by
Western blotting on the right. (C) DSBs
were measured as above in hTERT-im-
mortalized 1-BR fibroblasts and 850-BR
fibroblasts and in the latter cells after
transfection with the empty GFP vector
or vector encoding recombinant human
TDP2-GFP. The level of TDP2 and actin
(loading control) in the cell lines used for
these experiments is shown byWestern
blotting on the right. Data are mean ±
SEMof 3 independent experiments, and
statistically significant differences were
determined by the t test (ns = not sig-
nificant, *p < 0.05; **p < 0.01; ***p <
0.001). DSB = double-strand break;
GFP = green fluorescent protein; TDP2 =
tyrosyl DNA phosphodiesterase 2.
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850-BR cell extract, compared with reactions supplemented
with reaction buffer alone, reflects nucleases in the cell extract
rather than residual TDP2 activity because similar results were
observed when we used cell extract from human cells in which
TDP2 was deleted by CRISPR/Cas9 (unpublished observa-
tions). The lack of TDP2 activity in patient cells did not
reflect differences in the technical quality of cell extracts be-
cause the level of TDP1 activity in these extracts was similar to
that in normal human 1-BR fibroblasts (figure 2D). We
conclude from these data that the TDP2 splice site mutation
greatly reduces and most likely ablates both TDP2 protein
and activity in 850-BR patient fibroblasts.
Next, we addressed the impact of the TDP2 splice site mu-
tation on nuclear DSB repair rates in 850-BR patient fibro-
blasts using immunofluorescent detection of γH2AX as an
indirect measure of DSBs.12 Although similar levels of nuclear
γH2AX foci were present in normal and patient fibroblasts
immediately after treatment with etoposide for 30 minutes,
the levels of these γH2AX foci decreased far more slowly in
the patient fibroblasts during subsequent incubation in a drug-
free medium (figure 3A). However, DSB repair was com-
pleted in patient cells within 8–24 hours, consistent with the
established existence of alternative, nuclease-dependent
mechanisms for repair of TOP2-induced DSBs in human
cells.4,13,14 Similar results were observed in human A549 cells
in which TDP2 was mutated by CRISPR/Cas9 gene editing,
confirming the importance of TDP2 for repair of TOP2-
induced DSBs (figure 3B). More importantly, complemen-
tation of 850-BR cells with expression construct encoding
recombinant human TDP2 restored normal rates of nuclear
DSB repair, confirming that the DNA repair defect in the
patient fibroblasts was the result of theTDP2mutation (figure
3C). This defect in DSB repair was accompanied by cellular
hypersensitivity to TOP2-induced DSBs because both 850-
BR patient fibroblasts and TDP2−/− A549 cells were hyper-
sensitive to etoposide in clonogenic survival assays (figure 4, A
and B). In contrast to etoposide-induced DSBs, both DSB
repair rates and levels of cell survival were normal in 850-BR
patient fibroblasts after treatment with ionizing radiation
(figure 4, C and D), confirming the specificity of the DNA
repair defect in the patient’s cells for DNA breaks induced by
TOP2.
Finally, because analyses of muscle biopsy from the patient
(see the case report) suggested the presence of possible
defects in the ETC, we examined 850-BR patient fibroblasts
for defects in mitochondrial function. However, the patient
Figure 4Hypersensitivity of TDP2-mutated patient fibroblasts andA549 cells to DNAdamage induced by etoposide but not
γ-rays
(A) Clonogenic survival of 1-BR normal
and 850-BR patient primary fibro-
blasts in a medium containing the in-
dicated concentrations of etoposide.
(B) Clonogenic survival of wild-type
A549 and TDP2−/− A549 cells in a me-
dium containing the indicated con-
centrations of etoposide. (C)
Clonogenic survival of 1-BR normal
and 850-BR patient primary fibro-
blasts as above, following γ-irradia-
tion. (D), DSBs were measured by
γH2AX immunostaining in normal 1-
BR and patient 850-BR primary fibro-
blasts before and after the indicated
periods after γ-irradiation (2 Gy). Data
are mean ± SEM of 3 independent
experiments, and statistically signifi-
cant differences were determined by
two-way ANOVA (ns = not significant,
***p < 0.001). TDP2 = tyrosyl DNA
phosphodiesterase 2.
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fibroblasts failed to exhibit significant defects in respiratory
chain complexes in biochemical assays compared with
a range of different normal (control) human fibroblasts
(figure 5A.a). Similar results were observed when we
compared wild-type A549 cells with A549 cells in which
TDP2 was mutated by gene editing (figure 5A.b). We also
failed to identify any impact of the TDP2 mutation or de-
letion in 850-BR fibroblasts and A549 cells, respectively, in
the level of respiratory chain proteins as measured by im-
munoblotting (figure 5B).
Figure 5 Mitochondrial functionality in normal and TDP2-mutated cells
(A) Activity ofmitochondrial respiratory
complexes in normal (red bars) and
patient 850-BR (blue bars) primary
human fibroblasts (A.a) and in wild-
type human A549 (red bars) and
TDP2−/− A549 cells (blue bars) (A.b) was
determined as previously described.15
The mean enzyme activities in control
cells (n = 8) are set to 100%, and error
bars represent SD. (B) Levels of mito-
chondrial respiratory complex pro-
teins in age-matched control
fibroblasts (C1 andC2) andpatient 850-
BR fibroblasts (B.a) and in wild-type
A549 cells and TDP2−/− A549 cells (B.b),
as measured by immunoblotting for
subunits of CI (NDUFB8), CII (SDHA), CIII
(UQCRC2), CIV (COXI), and CV (ATP5A)
and using VDAC1 as a mitochondrial
loading control. (C) Subcellular locali-
zation of TDP2 in HeLa cells (C.a) and in
normal (1-BR) and patient (850-BR)
primary human fibroblasts (C.b). Left,
cell-equivalent amounts of HeLa total
cell lysate (30 g total protein; lane 1),
cell lysate depleted of mitochondria
(“post-mito spin”; lane 2), mitochondria
treated with proteinase K (to remove
proteins associated with the outer
membrane; lane 3), mitoplasts (mito-
chondrial matrix plus inner membrane
proteins; lane 4), mitoplasts treated
with proteinase K (lane 5), and inner
membrane mitochondrial proteins
(extractedwith sodium carbonate; lane
6) were immunoblotted for TDP2 and
for protein markers of the cytosol
(eIF4E) and each of the mitochondrial
compartments, intermembrane space
(AIF), mitochondrial matrix (EF-Tu), and
inner mitochondrial membrane
(NDUFB8). Right, cell-equivalent
amounts of 1-BR or 850-BR fibroblast
total cell lysates (30μg protein) de-
pleted of mitochondria (“post-mito
spin”) and of mitoplasts were immu-
noblotted for TDP2 as above. The po-
sition of full-length TDP2 (arrow) and
a nonspecific band detected by the
antibody (asterisk; *) are indicated.
TDP2 = tyrosyl DNA phosphodiester-
ase 2.
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We next fractionated HeLa cells and both 1-BR and 850-BR
fibroblasts into subcellular components, including intact mi-
tochondria and mitoplasts, to examine whether TDP2 is lo-
cated within the mitochondria and thus in the correct location
to repair mitochondrial DNA (figure 5C). Most of the ma-
terial detected by the anti-TDP2 antibody and whichmigrated
to the position expected for TDP2 was present, as expected, in
the cellular fractions containing cytosolic and nuclear proteins
(figure 5C.a, lanes 1 and 2). However, a very small amount of
this material was detected in intact mitochondria and mito-
plasts (figure 5C.a, lanes 3–5). In 1-BR normal human
fibroblasts, most of the material detected by anti-TDP2 an-
tibody was again present in the cytosolic/nuclear fraction, and
this material was TDP2 because it was absent from parallel
preparations from patient 850-BR fibroblasts (figure 5C.b).
However, if TDP2 was present in mitoplasts prepared from
1-BR cells, it was below the level of detection in our experi-
ments (figure 5C.b, arrow). We did note the presence of
a slower migrating band that was detected by the TDP2 an-
tibody in both HeLa and 1-BR mitoplasts, but this band was
also present in parallel preparations from 850-BR patient
fibroblasts, indicating that it was not TDP2 (figure 5C.b,
asterisk). Collectively, although we cannot rule out the pres-
ence of a small amount of endogenous TDP2 in mitochon-
dria, we cannot detect defects in mitochondrial function in
SCAR23 patient fibroblasts. Consequently, we suggest that
the neurologic disease pathology in SCAR23 is most likely the
result of a defect in nuclear DSB repair.
Discussion
We recently identified TDP2 mutations in a recessive hered-
itary genetic disorder associated with intellectual disability,
seizures, and ataxia, now denoted as spinocerebellar ataxia
autosomal recessive 23 (SCAR23)6. In the three Irish siblings
originally described, we also identified the mutation c.914AG
(p.His305Arg) in ZNF193, a zinc finger protein of unknown
function, which we concluded was not disease causing but
which we could not exclude as a contributor to the disease.6
However, in contrast to the Irish patients, the new patient
identified in the United States and reported here harbors the
same TDP2-associated haplotype but lacks the mutation in
ZNF193, ruling out a contribution of the latter and confirming
the TDP2 mutation as the cause of SCAR23.
The TDP2-mutated patient fibroblasts established here are the
first such reported and have provided valuable information
concerning the molecular and cellular defect in SCAR23.
Consistent with TDP2 defects in other cell types, we observed
reduced rates of DSB repair and elevated cellular sensitivity
after treatment with the TOP2 poison etoposide. These phe-
notypes were the result of the TDP2 mutation in the patient
fibroblasts because they were phenocopied in TDP2−/− A549
cells created by gene editing and were complemented by the
reintroduction of the wild-type human TDP2 transgene. Of
interest, the magnitude of these phenotypes is greater in patient
fibroblasts and gene-edited A549 cells than what we have seen
previously with our previous gene-edited cell lines.9 We believe
that this is because the cell lines reported here are effectively
TDP2 null, whereas our previously generated TDP2 gene-
edited human cells retained a minor isoform of TDP2 that is
expressed at low levels and is primarily cytoplasmic.
It is notable that TOP2 poisons are used widely in the clinic to
treat a variety of cancers, and we point out that the use of these
agents in patients with TDP2 mutations should be avoided or
at the very least treated with extreme caution. Although
TDP2-defective cancer cells will be hypersensitive to this type
of chemotherapy, normal cells will also be hypersensitive, as
illustrated in the current work by the etoposide sensitivity
observed in both TDP2−/− A549 lung cancer cells and
SCAR23 primary fibroblasts.
The presence of mitochondrial dysfunction in the SCAR23
patient described here is suggested by ETC studies and the high
lactate and lactate/pyruvate ratio in muscle (see the Patient
Case Study in the Methods section). In addition, the current
patient exhibits phenotypes consistent with mitochondrial
dysfunction such as hypotonia, low energy, and fatigability. It is
unclear whether phenotypes consistent with mitochondrial
defects are also present in the Irish patients, although none
were originally noted.6 Unfortunately, neither fibroblasts nor
muscle biopsy are available from these patients to address this
possibility. The lack of detectable mitochondrial defect in pri-
mary skin fibroblasts from the current patient and in gene-
edited A549 cells does not support amajor role for TDP2 in the
repair of mitochondrial DNA. However, the absence of mito-
chondrial defects in skin fibroblasts from patients with mito-
chondrial defects in muscle is not uncommon.15 Nevertheless,
given the dramatic impact of the TDP2 mutation on nuclear
DNA repair, we suggest that any association of SCAR23 with
mitochondrial disease is most likely an indirect or secondary
dysfunction resulting from a nuclear disorder.16
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